Clinical trial NCT03999554: Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
Official title: Phase 1b Clinical Study to Investigate the Safety and Immunogenicity of the Bris10 (A/Brisbane/10/2007) M2SR and Sing2016 (A/Singapore/INFIMH-16-0019/2016) M2SR H3N2 Monovalent Influenza Vaccines
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Influenza A
Lead sponsor: FluGen Inc
Sponsor class: INDUSTRY
First posted: 2019-06-26
Enrollment: 206
Sex: ALL
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: This is a randomized, double-blind, placebo-controlled Phase 1 study evaluating the safety and immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 influenza vaccines delivered intranasally to healthy adults. Eligible subjects will be screened and randomized to receive two administrations 28 days apart of Sing2016 M2SR at three dose levels, Bris10 M2SR at one dose level, or placebo in a 1:1:1:1:1 ratio.
Primary purpose: BASIC_SCIENCE

Brief summary: This is a Phase I double-blind, randomized, placebo-controlled study in 250 healthy adults, 18-49 years of age, inclusive, who are in good health and meet all eligibility criteria. The purpose of this dose escalation clinical study is to assess the safety, tolerability/reactogenicity, and immunogenicity of H3N2 M2SR investigational vaccines for prevention of influenza, when delivered at higher dosages or in two doses . Eligible subjects will be screened and randomized to receive two administrations 28 days apart of Sing2016 M2SR at three dose levels (low, medium, high), Bris10 M2SR at one dose level (low), or placebo in a 1:1:1:1:1 ratio. Study duration will be approximately 8 months with subject participation duration approximately 7 months. The primary study objective is to assess the safety and reactogenicity of a monovalent live single replication influenza H3N2 M2SR vaccine.

Detailed description: This is a Phase I double-blind, randomized, placebo-controlled study in 250 healthy adults, 18-49 years of age, inclusive, who are in good health and meet all eligibility criteria. This dose escalation clinical study is designed to assess the safety, tolerability/reactogenicity, and immunogenicity of H3N2 M2SR investigational vaccines for prevention of influenza, when delivered at increasing dosages or in two doses. Subjects will be enrolled in five groups in a 1:1:1:1:1 ratio. Arm 1 will receive a low dose of Sing2016 M2SR intranasally on days 1 and 29. Arm 2 will receive a medium dose of Sing2016 M2SR intranasally on days 1 and 29. Arm 3 will receive a high dose of Sing2016 M2SR intranasally on days 1 and 29. Arm 4 will receive a low dose of Bris16 M2SR intranasally on days 1 and 29. Arm 5 will receive a placebo intranasally on days 1 and 29. Study duration will be approximately 8 months with subject participation duration approximately 7 months. The primary study objective is to assess the safety and reactogenicity of a monovalent live single replication influenza H3N2 M2SR vaccine. The secondary study objectives are to evaluate systemic and mucosal immune responses induced by H3N2 M2SR vaccination.

Eligibility criteria: Inclusion Criteria:

1. Give written informed consent to participate.
2. Age 18 - 49 years old.
3. Judged suitable by the PI, as determined by medical history, physical examination, vital signs, and clinical safety laboratory examinations.
4. Willing to use oral, implantable, transdermal or injectable contraceptives, or sexual abstinence, from screening and until 28 days after second vaccine dose.
5. Willing to adhere to the requirements of the study and willing and able to communicate with the Investigator and understand the requirements of the study.

Exclusion Criteria:

1. Abnormal screening hematology or chemistry value per the FDA Toxicity Guidance.
2. Pulse rate or blood pressure outside the reference range for this study population and considered as clinically significant by the Investigator.
3. Has an acute or chronic medical condition or history of a medical condition that, in the opinion of the Investigator, would render the study procedures unsafe or would interfere with the evaluation of the responses.
4. Presence or clinically significant history of lung disease, asthma, chronic obstructive pulmonary disease (COPD), or otherwise poor lung function.
5. Any confirmed or suspected immunosuppressive or immunodeficient state.
6. Presence of household member or close personal or professional (i.e., healthcare worker) who is a child under one year of age; is pregnant; has known immunodeficiency or is receiving immunosuppressant medication; is undergoing or soon to undergo cancer chemotherapy; has been diagnosed with emphysema, COPD, or other severe lung disease and resides in a nursing home; and/or has received a bone marrow or solid organ transplant.
7. Females who are pregnant or lactating.
8. Acute febrile illness within 72 hours prior to vaccination.
9. Any condition, in the opinion of the Investigator, (such as subjects who have medically high-risk conditions) that might interfere with the primary study objectives for safety of the study subject.

Primary outcomes:
measure: Number of Participants With Local and Systemic Adverse Events (AEs) Through 29 Days Post-vaccination With Bris10 M2SR and Cumulatively Through Day 209
timeFrame: From baseline through study completion (Day 209)
measure: Number of Participants With Local and Systemic Adverse Events (AEs) Through 29 Days Post-vaccination With Sing2016 M2SR and Cumulatively Through Day 209
timeFrame: From baseline through study completion (Day 209)
Secondary outcomes:
measure: Percentage of Bris10 M2SR Subjects Demonstrating Seroconversion to Vaccine HA
timeFrame: From baseline through 28 days post-dose 1 (Day 29)
measure: Percentage of Sing2016 M2SR Subjects Demonstrating Seroconversion to Vaccine HA
timeFrame: From baseline through 28 days post-dose 1 (Day 29)
measure: Percentage of Bris10 M2SR Subjects Demonstrating Seroconversion to Vaccine HA
timeFrame: From baseline through 28 days post-dose 2 (Day 57)
measure: Percentage of Sing2016 M2SR Subjects Demonstrating Seroconversion to Vaccine HA
timeFrame: From baseline through 28 days post-dose 2 (Day 57)
measure: Percentage of Bris10 M2SR Subjects Demonstrating Mucosal Responses to Vaccine HA
timeFrame: From baseline through 28 days post-dose 1 (Day 29)
measure: Percentage of Bris10 M2SR Subjects Demonstrating Mucosal Responses to Vaccine HA
timeFrame: From baseline through 28 days post-dose 2 (Day 57)
measure: Percentage of Sing2016 M2SR Subjects Demonstrating Mucosal Responses to Vaccine HA
timeFrame: From baseline through 28 days post-dose 2 (Day 57)
measure: Percentage of Sing2016 M2SR Subjects Demonstrating Mucosal Responses to Vaccine HA
timeFrame: From baseline through 28 days post-dose 1 (Day 29)
Other outcomes:
Locations:
city: Hollywood
country: United States
facility: RCA
state: Florida
city: Lenexa
country: United States
facility: JCCT
state: Kansas
city: Lexington
country: United States
facility: AMR Lexington
state: Kentucky
city: Norfolk
country: United States
facility: AMR Norfolk
state: Virginia
Study officials:
affiliation: FluGen Inc
name: Pamuk Bilsel
role: STUDY_DIRECTOR
affiliation: JCCT
name: Carlos Fierro, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Eiden J, Fierro C, Schwartz H, Adams M, Ellis KJ, Aitchison R, Herber R, Hatta Y, Marshall D, Moser MJ, Belshe R, Greenberg H, Coelingh K, Kawaoka Y, Neumann G, Bilsel P. Intranasal M2SR (M2-Deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in Adults. J Infect Dis. 2022 Dec 28;227(1):103-112. doi: 10.1093/infdis/jiac433.